Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MedX Health ( (TSE:MDX) ) has issued an update.
MedX Health Corp. has announced a strategic partnership with Vitamed Biomedical and Medispa to expand its teledermatology services in Italy. This collaboration will deploy MedX’s SIAscope on DermSecure platform across Medispa’s network, enhancing access to advanced skin screening and preventive care. The initiative is part of MedX’s international growth strategy, aiming to improve early melanoma detection through non-invasive methods. Italy is a significant growth market for MedX, with increasing demand for accessible dermatological screening due to heightened awareness of skin cancer risks.
More about MedX Health
MedX Health Corp., based in Ontario, Canada, is a prominent developer of non-invasive skin analysis and teledermatology solutions. The company’s SIAscopy technology, part of the DermSecure platform, allows for pain-free imaging of skin lesions for swift remote dermatologist evaluation. MedX’s products are approved for use in several markets, including Canada, the United States, Europe, and Australia.
Average Trading Volume: 105,107
Technical Sentiment Signal: Buy
Current Market Cap: C$20.01M
For a thorough assessment of MDX stock, go to TipRanks’ Stock Analysis page.